Acute bacterial skin and skin structure infection

Results 271 to 280 of about 127,480 (296)

Some of the next articles are maybe not open access.

New Gram Positive Agents to Treat Acute Bacterial Skin and Skin Structure Infections.

Connecticut medicine, 2016
The FDA guidance published in 2013 provided requirements for conducting ABSSSI trials. In 2014, dalbavancin, oritavancin, and tedizolid were introduced into the market after phase III noninferiority clinical trials against vancomycin (for the lipoglycopeptides) and linezolid (for tedizolid), demonstrating clinical efficacy for the treatment of ABSSSI ...
Rosanna, Li, Michael D, Nailor
openaire +1 more source

Tedizolid phosphate for the treatment of acute bacterial skin and skin structure infections.

Drugs of today (Barcelona, Spain : 1998), 2017
Acute bacterial skin and skin structure infections (ABSSSI) are associated with remarkable morbidity, and often require hospitalization. The cause of most ABSSSI is aerobic Gram-positive cocci, including Staphylococcus aureus, and β-hemolytic streptococci. Tedizolid phosphate is a novel oxazolidinone prodrug whose active moiety is tedizolid.
openaire +1 more source

Cellulitis, Acute Bacterial Skin and Skin Structure Infection (ABSSSI)

2019
openaire +2 more sources

Dalbavancin vs SOC for acute bacterial skin and skin structure infections

PharmacoEconomics & Outcomes News, 2020
openaire +1 more source

Single-Dose Oritavancin in the Treatment of Acute Bacterial Skin Infections

New England Journal of Medicine, 2014
Heidi Kabler, Sandeep Gupta, Ashwin Porwal +2 more
exaly

Identifying patients with acute bacterial skin and skin structure infection who need blood cultures